Urgent

Invasive candidiasis & antifungal therapy (ICU)

ICU antifungal · Critical Care / ICU
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Invasive candidiasis (candidaemia and deep-seated infection) is a leading ICU fungal infection in patients with central lines, broad-spectrum antibiotics, parenteral nutrition, abdominal surgery or immunosuppression. Early echinocandin therapy, source control and line removal improve survival; empirical antifungals in undifferentiated sepsis should be risk-stratified rather than routine.

Red flags

  • Persistent candidaemia despite therapy (seek endocarditis/thrombophlebitis)
  • Candida endophthalmitis
  • Septic shock in a high-risk host
  • Fluconazole-resistant species (C. glabrata/krusei/auris)
  • Failure of source control

Assessment

Differential diagnosis

  • Candidaemia
  • Intra-abdominal candidiasis
  • Catheter-related candida infection
  • Invasive aspergillosis (immunocompromised/influenza/COVID)
  • Bacterial sepsis
  • Candida colonisation (not infection)

Investigations

  • Blood cultures (repeated)
  • Beta-D-glucan (adjunct, not standalone)
  • Cultures from sterile sites / intra-abdominal samples
  • Dilated fundoscopy for endophthalmitis in candidaemia
  • Echocardiography if persistent candidaemia
  • Risk score / colonisation assessment

Management

  • Identify risk factors: central venous catheter, prolonged broad-spectrum antibiotics, TPN, abdominal surgery, dialysis, immunosuppression, prolonged ICU stay
  • Take blood cultures and relevant site cultures before starting therapy
  • Start an echinocandin as first-line empirical and targeted therapy for suspected/confirmed invasive candidiasis
  • Remove or exchange central venous catheters promptly in candidaemia where feasible
  • Achieve source control for intra-abdominal infection (drainage/surgery)
  • De-escalate to fluconazole once the isolate is confirmed susceptible and the patient is stable
  • Arrange dilated retinal examination to exclude ocular involvement
  • Repeat blood cultures to document clearance and time the treatment duration from first negative culture
  • Treat candidaemia for at least 14 days after the first negative culture and resolution of signs
  • Consider invasive aspergillosis in immunocompromised or severe viral pneumonia and switch to mould-active therapy if suspected
  • Review antifungal stewardship and de-escalate or stop if infection excluded

Drugs & doses

Caspofungin 70 mg IV loading then 50 mg IV daily
Anidulafungin 200 mg IV loading then 100 mg IV daily
Micafungin 100 mg IV daily
Fluconazole 800 mg (12 mg/kg) IV loading then 400-800 mg daily (step-down if susceptible)
Liposomal amphotericin B 3-5 mg/kg/day IV (resistant/alternative)
Voriconazole 6 mg/kg IV 12 hourly x2 then 4 mg/kg 12 hourly (aspergillosis)

Disposition

ICU with infectious diseases/microbiology input and antifungal stewardship; ophthalmology review for candidaemia.

Complications & pitfalls

  • Endophthalmitis and visual loss
  • Endocarditis / deep abscess
  • Septic thrombophlebitis
  • Metastatic infection
  • Death

Exam pearls

  • Echinocandins are first-line empirical therapy for invasive candidiasis in critically ill patients
  • Remove the central line - retained catheters prolong candidaemia and worsen outcomes
  • Count the treatment course from the first negative blood culture, not from day one of therapy
  • Beta-D-glucan supports but does not confirm the diagnosis; use it alongside clinical risk

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.